Literature DB >> 8548898

Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans.

C J Cooper1, M J Landzberg, T J Anderson, F Charbonneau, M A Creager, P Ganz, A P Selwyn.   

Abstract

BACKGROUND: Endothelium-derived nitric oxide (NO) may be an important mediator of vascular resistance in the pulmonary circulation. We tested the hypotheses that in conscious adults the endothelium, through NO production, is important in maintaining basal pulmonary vascular resistance and that it can increase NO production further in response to receptor-mediated stimulation, leading to further vasodilation. METHODS AND
RESULTS: Pulmonary arterial resistance vessel function was studied within the distribution of a segmental lower lobe pulmonary artery in eight conscious adults 37 to 76 years old who were undergoing cardiac catheterization. Segmental blood flow was determined with use of a Doppler-tip guide wire and quantitative angiography. Drugs were administered locally within the segmental artery through an infusion catheter. NG-Monomethyl-L-arginine (L-NMMA) was used as a specific inhibitor of NO production, whereas acetylcholine (ACh) was used to test receptor-mediated vasodilation. To demonstrate that vasodilation to ACh was NO dependent, ACh response was tested alone, in the presence of L-NMMA, and in the presence of a control constrictor phenylephrine. Basal pulmonary vascular resistance was NO dependent because L-NMMA infusion resulted in a dose-dependent decrease in local flow velocity (P < .005), with flow decreasing 33% at the highest dose of L-NMMA. ACh infusion resulted in a dose-dependent increase in flow velocity (P = .001). The ACh response was at least in part NO dependent because it was diminished by the presence of L-NMMA (P < .05). The effect of L-NMMA on the ACh response was not due to nonspecific preconstriction because L-NMMA diminished the ACh response significantly more than did the endothelium-independent constrictor phenylephrine (P < .05) despite comparable preconstriction.
CONCLUSIONS: In healthy conscious adults, (1) normal basal pulmonary resistance is maintained in part by continuous local production of NO and (2) the local NO production is responsive to receptor-mediated stimulation, leading to further vasodilation, and can be tested with ACh.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8548898     DOI: 10.1161/01.cir.93.2.266

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  20 in total

Review 1.  Right ventricular afterload and the role of nitric oxide metabolism in left-sided heart failure.

Authors:  Matthias Dupont; W H Wilson Tang
Journal:  J Card Fail       Date:  2013-09-05       Impact factor: 5.712

Review 2.  Pulmonary vasodilation in acute and chronic heart failure: empiricism and evidence.

Authors:  Maya Guglin
Journal:  Curr Heart Fail Rep       Date:  2011-09

3.  Arginine metabolic endotypes in pulmonary arterial hypertension.

Authors:  Christina C Kao; Samuel H Wedes; Jean W Hsu; Kurt M Bohren; Suzy A A Comhair; Farook Jahoor; Serpil C Erzurum
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

4.  Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease.

Authors:  Claudia R Morris; Gregory J Kato; Mirjana Poljakovic; Xunde Wang; William C Blackwelder; Vandana Sachdev; Stanley L Hazen; Elliott P Vichinsky; Sidney M Morris; Mark T Gladwin
Journal:  JAMA       Date:  2005-07-06       Impact factor: 56.272

Review 5.  Novel methods in pulmonary hypertension phenotyping in the age of precision medicine (2015 Grover Conference series).

Authors:  Jarrod W Barnes; Adriano R Tonelli; Gustavo A Heresi; Jennie E Newman; Noël E Mellor; David E Grove; Raed A Dweik
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

6.  Perinatal changes in superoxide generation in the ovine lung: Alterations associated with increased pulmonary blood flow.

Authors:  Shruti Sharma; Sanjiv Kumar; Dean A Wiseman; Suphin Kallarackal; Sumant Ponnala; Manal Elgaish; Jing Tian; Jeffrey R Fineman; Stephen M Black
Journal:  Vascul Pharmacol       Date:  2010-03-31       Impact factor: 5.773

Review 7.  New trial designs and potential therapies for pulmonary artery hypertension.

Authors:  Mardi Gomberg-Maitland; Todd M Bull; Rajeev Saggar; Robyn J Barst; Amany Elgazayerly; Thomas R Fleming; Friedrich Grimminger; Maurizio Rainisio; Duncan J Stewart; Norman Stockbridge; Carlo Ventura; Ardeschir H Ghofrani; Lewis J Rubin
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

8.  Things We "kNOw" and Do Not "kNOw" about Pulmonary Hypertension.

Authors:  Jarrod W Barnes; Rakesh P Patel
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

9.  Wall stretch and thromboxane A₂ activate NO synthase (eNOS) in pulmonary arterial smooth muscle cells via H₂O₂ and Akt-dependent phosphorylation.

Authors:  Hae Jin Kim; Hae Young Yoo; Ji Hyun Jang; Hai Yue Lin; Eun Yeong Seo; Yin Hua Zhang; Sung Joon Kim
Journal:  Pflugers Arch       Date:  2016-01-04       Impact factor: 3.657

10.  Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction.

Authors:  Roshan P Weerackody; David J Welsh; Roger M Wadsworth; Andrew J Peacock
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-06       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.